IQVIA Holdings Past Earnings Performance
Past criteria checks 4/6
IQVIA Holdings has been growing earnings at an average annual rate of 34.8%, while the Life Sciences industry saw earnings growing at 15.3% annually. Revenues have been growing at an average rate of 7.7% per year. IQVIA Holdings's return on equity is 20.2%, and it has net margins of 9.2%.
Key information
34.8%
Earnings growth rate
35.9%
EPS growth rate
| Life Sciences Industry Growth | 19.5% |
| Revenue growth rate | 7.7% |
| Return on equity | 20.2% |
| Net Margin | 9.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How IQVIA Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 15,315 | 1,405 | 2,085 | 0 |
| 30 Jun 24 | 15,155 | 1,423 | 2,065 | 0 |
| 31 Mar 24 | 15,069 | 1,357 | 2,038 | 0 |
| 31 Dec 23 | 14,984 | 1,358 | 2,043 | 0 |
| 30 Sep 23 | 14,855 | 1,116 | 2,047 | 0 |
| 30 Jun 23 | 14,681 | 1,096 | 2,062 | 0 |
| 31 Mar 23 | 14,494 | 1,055 | 2,063 | 0 |
| 31 Dec 22 | 14,410 | 1,091 | 2,038 | 0 |
| 30 Sep 22 | 14,307 | 1,182 | 1,997 | 0 |
| 30 Jun 22 | 14,136 | 1,160 | 1,978 | 0 |
| 31 Mar 22 | 14,033 | 1,079 | 1,977 | 0 |
| 31 Dec 21 | 13,874 | 966 | 1,931 | 0 |
| 30 Sep 21 | 13,536 | 767 | 1,886 | 0 |
| 30 Jun 21 | 12,931 | 607 | 1,848 | 0 |
| 31 Mar 21 | 12,014 | 409 | 1,797 | 0 |
| 31 Dec 20 | 11,359 | 279 | 1,762 | 0 |
| 30 Sep 20 | 10,956 | 176 | 1,759 | 0 |
| 30 Jun 20 | 10,939 | 132 | 1,694 | 0 |
| 31 Mar 20 | 11,158 | 215 | 1,699 | 0 |
| 31 Dec 19 | 11,088 | 191 | 1,711 | 0 |
| 30 Sep 19 | 10,881 | 244 | 1,669 | 0 |
| 30 Jun 19 | 10,706 | 247 | 1,703 | 0 |
| 31 Mar 19 | 10,533 | 248 | 1,691 | 0 |
| 31 Dec 18 | 10,412 | 259 | 1,692 | 0 |
| 30 Sep 18 | 10,245 | 1,217 | 1,738 | 0 |
| 30 Jun 18 | 10,117 | 1,245 | 1,699 | 0 |
| 31 Mar 18 | 9,905 | 1,246 | 1,644 | 0 |
| 31 Dec 17 | 9,702 | 1,277 | 1,605 | 0 |
| 30 Sep 17 | 9,133 | 72 | 1,528 | 0 |
| 30 Jun 17 | 7,804 | 84 | 1,345 | 0 |
| 31 Mar 17 | 6,616 | 108 | 1,192 | 0 |
| 31 Dec 16 | 6,815 | 72 | 1,013 | 0 |
| 30 Sep 16 | 4,540 | 397 | 761 | 0 |
| 30 Jun 16 | 4,497 | 409 | 785 | 0 |
| 31 Mar 16 | 4,404 | 408 | 795 | 0 |
| 31 Dec 15 | 4,326 | 387 | 815 | 0 |
| 30 Sep 15 | 4,262 | 371 | 902 | 0 |
| 30 Jun 15 | 4,229 | 352 | 890 | 0 |
| 31 Mar 15 | 4,191 | 353 | 883 | 0 |
| 31 Dec 14 | 4,165 | 357 | 781 | 0 |
| 30 Sep 14 | 4,106 | 341 | 890 | 0 |
| 30 Jun 14 | 3,977 | 315 | 871 | 0 |
| 31 Mar 14 | 3,886 | 268 | 880 | 0 |
| 31 Dec 13 | 3,808 | 227 | 830 | 0 |
Quality Earnings: I1QV34 has high quality earnings.
Growing Profit Margin: I1QV34's current net profit margins (9.2%) are higher than last year (7.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: I1QV34's earnings have grown significantly by 34.8% per year over the past 5 years.
Accelerating Growth: I1QV34's earnings growth over the past year (25.9%) is below its 5-year average (34.8% per year).
Earnings vs Industry: I1QV34 earnings growth over the past year (25.9%) exceeded the Life Sciences industry -2.3%.
Return on Equity
High ROE: Whilst I1QV34's Return on Equity (20.17%) is high, this metric is skewed due to their high level of debt.